1. Home
  2. CE vs CRSP Comparison

CE vs CRSP Comparison

Compare CE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celanese Corporation

CE

Celanese Corporation

HOLD

Current Price

$48.04

Market Cap

4.5B

Sector

Industrials

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$54.27

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CE
CRSP
Founded
1918
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.1B
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
CE
CRSP
Price
$48.04
$54.27
Analyst Decision
Buy
Buy
Analyst Count
17
19
Target Price
$55.82
$71.50
AVG Volume (30 Days)
1.8M
1.7M
Earning Date
02-17-2026
02-10-2026
Dividend Yield
0.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,710,000,000.00
$38,337,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.14
$1,299.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.13
$30.04
52 Week High
$75.84
$78.48

Technical Indicators

Market Signals
Indicator
CE
CRSP
Relative Strength Index (RSI) 63.34 47.10
Support Level $43.73 $51.00
Resistance Level $47.89 $57.99
Average True Range (ATR) 2.13 2.63
MACD 0.21 -0.18
Stochastic Oscillator 94.79 33.50

Price Performance

Historical Comparison
CE
CRSP

About CE Celanese Corporation

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: